PTO SB/08x (08-03)
Approved for use through 07/31/2006 ONS 0651-0201
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB control number.

	Application Number			
	Filing Date			
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Chris		istopher William Wagstaffe	
Not for submission under 37 CFR 1.99)	Art Unit			
not of Submission and of St R 1.55y	Examiner Name			
	Attorney Docket Numb	er	7881.6	

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No				Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear					
	1									
If you wisl	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines wher ant Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	74
	1	482825	GB		A	1938-04-05	I. G. Farbenindush Aktiengesellschaft	rie		
	2	602112	FR		A	1926-03-12	Allis-Chalmers Manufacturing Cor	mpany		
	3	1157459	DE		В	1963-11-14	Esch-Werke K.G. Maschinenfabrik U Fisengiesserei	Ind	Figures 1-6	

	Application Number			
	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Chris		istopher William Wagstaffe	
(Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Numb	er	7881.6	

	4	1537210	FR	A	1968-08-23	Allis-Chalmers Manufacturing Company		
If you wis	h to a	dd additional Foreign F	atent Document	citation	information pl	ease click the Add buttor	Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publishers.						Τs	
	1							
If you wis	h to a	dd additional non-pater	nt literature docu	ment ci	tation informati	on please click the Add I	outton Add	
			EX	AMINE	R SIGNATUR	E		
Examiner	Signa	ture				Date Considered		
*EXAMIN	ER: Ir	itial if reference consid	ered, whether or	not cit	ation is in confi	ormance with MPEP 609	Draw line through a	

See Kint Codes of USPTO Patent Documents at Invent/ISPTO.QDV or MPEP 901.04. Enter office that issued the document, by the Nov-letter option Standard ST3.) For Explanates petal or Counters, the Indication of the year of the region or preceded to ever an order to the patent document. A found of countering the Counter of the Emperor may precede to see and not petalent document. If Nord of countering the propriet symbols as indicated on the document under WIPO Standard ST.16 if possible. Sppicant is to place a check mark here if Employin Israquing Personation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to keen of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

our of the signature.							
Signature	/Evan R. Witt/	Date (YYYY-MM-DD)	2006-08-25				
Name/Print	Evan R. Witt	Registration Number	32512				

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Afford, U.S. Department of Commence, P. 0. Bast 1450, Alexandria, V.S. 2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.